Phase III

A clinical trial to study the antibody response and tolerability of GARDASIL®9 in women aged 27 to 45 years old compared to women aged 16 to 26 years old

• EudraCT number:2015-005093-38
• ClinicalTrials.gov Identifier: NCT03158220
• Sponsor protocol number: V503-004
• Phase: III
• Population age: adolescents (<18), adults
• Gender: male, female
• Starting year @CEV: 2017

Randomized, Double-Blind, Active-Controlled Study in Adults to Assess the Safety and Immunogenicity of Abbott's Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority to Trivalent Influenza Vaccine

• EudraCT number:2014-001042-24
• Sponsor protocol number: INFQ3001
• Phase: III
• Population age: adults & elderly 
• Gender: male, female
• Starting year @CEV: 2015

Consistency, immunogenicity and safety study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) vaccine GSK1437173A in adults ≥ 50 years of age.

• EudraCT number: 2013-000373-76
• ClinicalTrials.gov Identifier: NCT02075515
• Sponsor protocol number:  117177 (ZOSTER-007)
• Centre code:  Zoster-007
• Phase: III
• Population age: adults (>49y)
• Gender: male,female
• Starting year @CEV: 2014

A study to compare immune response of V503 to Gardasil in 16- to 26-year-old men

• EudraCT number: 2013-003399-10
• ClinicalTrials.gov Identifier: NCT02114385
• Sponsor protocol number: GDS07C (HPV-V503-009)
• Centre code:
• Phase: III
• Population age: adolescents (16 to 26y)
• Gender: male
• Starting year @CEV: 2014

Immunogenicity and Lot-to-Lot Consistency Study of a Quadrivalent Influenza Vaccine in Adult and Elderly Subjects

• EudraCT number: 2014-000785-21
• Sponsor protocol number: GQM11
• Centre code:
• Phase: III
• Population age: adults (18 to 60y)
• Gender: male,female
• Starting year @CEV: 2014

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

• EudraCT number: 2013-000607-16
• ClinicalTrials.gov Identifier: NCT01879540
• Sponsor protocol number: V70_44S
• Centre code:
• Phase: III
• Population age: elderly (>64y)
• Gender: male, female
• Starting year @CEV: 2013

A Randomized, Double-Blinded, Controlled with GARDASIL® (Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Recombinant, adsorbed)), Phase III Clinical Trial to Study the Immunogenicity and Tolerability of V503 (9-Valent Human Papillomavirus [HPV]

• EudraCT number: 2010-023393-39
• Sponsor protocol number: GDS01C (HPV-V503-009)
• Centre code:
• Phase: III
• Population age: youngsters (9 to 15y)
• Gender: female
• Starting year @CEV: 2011